Literature DB >> 19197951

Determinants of response to epidermal growth factor receptor tyrosine kinase inhibition in squamous cell carcinoma of the head and neck.

Susanne J Rogers1, Carol Box, Philip Chambers, Yolanda Barbachano, Christopher M Nutting, Peter Rhŷs-Evans, Paul Workman, Kevin J Harrington, Suzanne A Eccles.   

Abstract

Dramatic responses to epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitors may be seen in non-small cell lung cancers (NSCLCs) with a sensitizing mutation of the EGFR TK domain. It is not known how to predict response in patients with squamous cell carcinoma of the head and neck (SCCHN), where EGFR TK mutations are less frequent and where response rates in unselected patients are disappointing. We have characterized the intrinsic sensitivity of a panel of 18 SCCHN cell lines to gefitinib, an EGFR TK inhibitor, and have investigated correlations between putative markers of response and intrinsic sensitivity. Induction of G1 arrest was only seen in cell lines with GI(50) < 1 microM. Expression of EGFR, by three techniques, correlated with sensitivity to gefitinib. ERB-B2 expression appeared to influence sensitivity to gefitinib but ERB-B3 expression did not. While EGFR tyrosine kinase mutations were not detected, EGFR gene amplification was confirmed by fluorescence in situ hybridization in the most sensitive cell line. The number of cytosine adenine dinucleotide repeats in intron 1 of the EGFR gene did not correlate with sensitivity. E-cadherin expression was detected in cell lines with a range of sensitivities, whereas amphiregulin was secreted predominantly by sensitive cell lines. MET expression was an independent predictor of sensitivity to gefitinib, although neither expression nor phosphorylation of insulin-like growth factor 1 receptor correlated with intrinsic resistance. Breast receptor kinase (BRK) was more highly expressed in the sensitive cell lines, but siRNA knockdown of neither BRK nor MET affected sensitivity. Our data suggest that overexpression of EGFR and multiple related cell surface receptors may be associated with sensitivity to gefitinib and that differences between our data and the literature highlight that biomarkers of response are tumour type- and cell line-dependent.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19197951     DOI: 10.1002/path.2515

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  13 in total

Review 1.  Pharmacogenomic discovery using cell-based models.

Authors:  Marleen Welsh; Lara Mangravite; Marisa Wong Medina; Kelan Tantisira; Wei Zhang; R Stephanie Huang; Howard McLeod; M Eileen Dolan
Journal:  Pharmacol Rev       Date:  2009-12       Impact factor: 25.468

2.  Small molecule inhibitors of the host cell COX/AREG/EGFR/ERK pathway attenuate cytomegalovirus-induced pathogenesis.

Authors:  Michael Melnick; George Abichaker; Khine Htet; Parish Sedghizadeh; Tina Jaskoll
Journal:  Exp Mol Pathol       Date:  2011-05-01       Impact factor: 3.362

3.  Optical molecular imaging of multiple biomarkers of epithelial neoplasia: epidermal growth factor receptor expression and metabolic activity in oral mucosa.

Authors:  Kelsey J Rosbach; Michelle D Williams; Ann M Gillenwater; Rebecca R Richards-Kortum
Journal:  Transl Oncol       Date:  2012-06-01       Impact factor: 4.243

4.  Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer.

Authors:  Mohammed Taoudi Benchekroun; Pierre Saintigny; Sufi M Thomas; Adel K El-Naggar; Vassiliki Papadimitrakopoulou; Hening Ren; Wenhua Lang; You-Hong Fan; Jianhua Huang; Lei Feng; J Jack Lee; Edward S Kim; Waun Ki Hong; Faye M Johnson; Jennifer R Grandis; Li Mao
Journal:  Cancer Prev Res (Phila)       Date:  2010-06-22

5.  Activation of the insulin-like growth factor-1 receptor induces resistance to epidermal growth factor receptor antagonism in head and neck squamous carcinoma cells.

Authors:  Mark J Jameson; Andrew D Beckler; Linnea E Taniguchi; Amir Allak; Lisa B Vanwagner; Nora G Lee; William C Thomsen; Matthew A Hubbard; Christopher Y Thomas
Journal:  Mol Cancer Ther       Date:  2011-08-30       Impact factor: 6.261

Review 6.  Building a better understanding of the intracellular tyrosine kinase PTK6 - BRK by BRK.

Authors:  Patrick M Brauer; Angela L Tyner
Journal:  Biochim Biophys Acta       Date:  2010-02-26

7.  Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition.

Authors:  Natalie R Young; Jing Liu; Carolyn Pierce; Tai-Fen Wei; Tatyana Grushko; Olufunmilayo I Olopade; Wanqing Liu; Christine Shen; Tanguy Y Seiwert; Ezra E W Cohen
Journal:  Mol Oncol       Date:  2012-11-14       Impact factor: 6.603

8.  Acquired resistance to EGFR tyrosine kinase inhibitors alters the metabolism of human head and neck squamous carcinoma cells and xenograft tumours.

Authors:  M Beloueche-Babari; C Box; V Arunan; H G Parkes; M Valenti; A De Haven Brandon; L E Jackson; S A Eccles; M O Leach
Journal:  Br J Cancer       Date:  2015-03-31       Impact factor: 7.640

9.  Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway.

Authors:  Katie Twigger; Victoria Roulstone; Joan Kyula; Eleni M Karapanagiotou; Konstantinos N Syrigos; Richard Morgan; Christine White; Shreerang Bhide; Gerard Nuovo; Matt Coffey; Brad Thompson; Adel Jebar; Fiona Errington; Alan A Melcher; Richard G Vile; Hardev S Pandha; Kevin J Harrington
Journal:  BMC Cancer       Date:  2012-08-24       Impact factor: 4.430

10.  Epidermal growth factor (EGF) receptor-ligand based molecular staging predicts prognosis in head and neck squamous cell carcinoma partly due to deregulated EGF- induced amphiregulin expression.

Authors:  Jian Gao; Camilla H Ulekleiv; Trond S Halstensen
Journal:  J Exp Clin Cancer Res       Date:  2016-09-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.